-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $87

Benzinga·12/22/2025 13:27:56
語音播報
Barclays analyst Gena Wang maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $82 to $87.